What is Kolon TissueGene?
Kolon TissueGene, Inc. is a pioneering cell and gene therapy company focused on developing innovative treatments for knee osteoarthritis (OA). The company's lead product, TG-C, is an allogeneic cell and gene therapy designed to address a significant unmet need in the market. With plans for two pivotal Phase III clinical trials in the U.S., including one under a Special Protocol Assessment (SPA) agreement with the FDA, Kolon TissueGene is positioning itself for substantial growth and market penetration in the regenerative medicine space.
How much funding has Kolon TissueGene raised?
Kolon TissueGene has raised a total of $29.6M across 1 funding round:
Other Financing Round
$29.6M
Other Financing Round (2022): $29.6M with participation from Kolon Group
Key Investors in Kolon TissueGene
Kolon Group
Kolon Group is a South Korean conglomerate with diverse business interests, including chemicals, materials, and pharmaceuticals. Their investment in Kolon TissueGene highlights a strategic focus on advancing innovative biotechnology and healthcare solutions within their portfolio.
What's next for Kolon TissueGene?
The recent major strategic investment signals a critical phase of scaling and clinical advancement for Kolon TissueGene. This capital infusion is expected to accelerate the progression of TG-C through its Phase III trials, bringing the company closer to potential commercialization. The company's focus on a first-in-class therapy for knee OA, backed by regulatory engagement with the FDA, suggests a strategic push towards establishing a dominant position in the orthopedic cell therapy market. Future developments will likely center on trial outcomes and the subsequent regulatory pathway.
See full Kolon TissueGene company page
